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Hs-CRP and TNF-alpha.Abstract Background: Chronic obstructive pulmonary disease (COPD) is a chronic progressive
inflammatory disease characterized by airflow limitation that is not fully reversible (Nillawar
et al., 2012). The pathophysiology of COPD is not completely understood. Cigarette smoking
is a major risk factor for chronic obstructive pulmonary disease (COPD). Elevated CRP has
been increasingly used as a surrogate marker of systemic inflammation in diverse conditions.
TNF-a, a powerful pro-inflammatory cytokine primarily produced by activated macrophages,
is thought to play a critical role in the pathogenesis of COPD (Higashimoto et al., 2008; Churg
et al., 2002).
The aim of the work: To evaluate the impact of smoking on inflammatory biomarkers and
relations between these biomarkers and the decline of lung function in COPD patients.
Methods: This case–control observational prospective study was conducted on fifty-eight clin-
ically stable COPD patients (26 non-smokers and 32 current smokers; at different stages ranged
from mild to very severe), their mean age 53.1 ± 14.25 and 53.9 ± 5.95 years respectively),
recruited from Chest Department, Assiut University Hospitals. All patients met the Global
Initiative for Obstructive Lung Disease (GOLD) (Battaglia et al., 2007). All participants were
subjected to thorough history taking, full clinical examination, anthropometric measurements
with spirometry and chest X-ray. Peripheral hemogram, liver function tests, kidney function
tests, high sensitivity C-reactive protein (hs CRP) and serum level of TNF-a were measured
for both patients and controls.
Results: The concentrations of circulating hs-CRP and TNF-a, were highly significantly elevated
in patients with COPD in comparison to the control group (3.74 ± 0.2 vs. 1.30 ± 0.14 for hs-CRP;, forced
, forced
, tumor
598 Y.A. Korani et al.33.88 ± 5.97 vs. 8.79 ± 0. 57 for TNF-awith p< 0.0001 for each) and the levels of measured TNF-a
were significantly increased with the increased degree and severity of COPD and increased severity of
smoking status. Regarding the smoking status of COPD patients, there was a highly significant dif-
ference for the measured TNF-a (53. 74 ± 9.52 versus 12.73 ± 1.20 with p< 0.0001) with no signif-
icant difference for the measured hs-CRP (3.87 ± 0.29 versus 3.58 ± 0.27 with p> 0.05).
Interestingly, there were significant negative correlations between the levels of TNF-a and hs-
CRP, and FEV1 in stages II, III, and IV of COPD.
Conclusions: The circulating levels of the inflammatory markers hs-CRP and TNF-alpha are sig-
nificantly elevated in patients with stable COPD and these biomarkers could be used as predictor fac-
tors for severity of inflammation in COPD patients. Longitudinal studies evaluating the effects of
smoking cessation on bronchial and systemic inflammation are needed to allow better understanding
of these relationships and their consequences.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is a syndrome
characterized and defined by a single physiological parameter:
limitation of expiratory air-flow which, most often, is slowly
progressive over the years. According to the widely accepted
definition from Global Initiative on Obstructive Lung Disease
(GOLD) COPD is ‘‘a disease state characterized by airflow
limitation that is not fully reversible. The airflow limitation
is usually progressive and associated with an abnormal inflam-
matory response of the lungs to noxious particles and gases”
[44]. COPD is a condition characterized by an abnormal
inflammatory response beyond the lungs with evidence of
low-grade systemic inflammation which causes systemic mani-
festations such as weight loss, skeletal muscle dysfunction, an
increased risk of cardiovascular disease, osteoporosis and
depression, among others [6,45]. Several studies have shown
systemic inflammation in COPD patients with increased neu-
trophil, macrophage, and T-lymphocyte numbers and high
concentrations of inflammatory mediators in peripheral blood
(C-reactive protein (CRP) and TNF-a) [11,1]. Airway inflam-
matory markers are higher in more severe disease and increase
during COPD exacerbations. However, no exhaled biomarker
has been widely used in clinical trials in COPD [7]. Kostikas
et al. [12] stated that systemic inflammation is present in stable
COPD and the intensity of the inflammatory process relates to
the severity of the underlying disease. In the interest of improv-
ing the diagnosis of COPD, several types of biomarker have
been measured that are related to disease pathophysiology
and the inflammatory and destructive process in the lung.
However, there is little information about biomarker repro-
ducibility and the relationship with disease development,
severity, or progression [9]. Several inflammatory markers such
as C-reactive protein (CRP), fibrinogen and IL-6, are increased
in patients with COPD in both stable disease and exacerba-
tions, with CRP being the most studied biomarker [5]. One
of the inflammatory markers which is increasingly evaluated
in COPD patients is CRP. CRP is an acute phase protein
synthesized predominantly by the hepatocytes in response to
tissue damage or inflammation. It has been accepted that levels
of CRP relate to the presence of airflow obstruction [44]. Very
little is known about the mechanism of increased TNF-a con-
centration in the plasma of COPD patients and its relationshipwith disease severity and active smoking has not been estab-
lished [9,15]. Tobacco smoking is the main risk factor of
chronic obstructive pulmonary disease (COPD) but not all
smokers develop the disease. An abnormal pulmonary and
systemic inflammatory response to smoking is thought to play
a major pathogenic role in COPD, but this has never been
tested directly. Yet, only a proportion of smokers, so called
‘‘susceptible smokers’’, develop the disease [42,3]. The genetic
and epigenetic background of each smoker is likely to regulate
the type and intensity of his/her inflammatory response to
smoking [10]. In ‘‘susceptible smokers’’, this response is
thought to be ‘‘enhanced’’, both in the lungs and in the sys-
temic circulation, and is believed to drive disease progression
[41]. However, despite the wide acceptance of this notion, no
previous study has actually studied the ‘‘response’’ to smoking
(i.e., the specific inflammatory changes that occur before and
after smoking) in susceptible smokers (i.e., patients with
COPD) and resistant smokers (i.e., smokers with normal
spirometry) [3]. Long-term smoking causes airway inflamma-
tion characterized by neutrophil, macrophage, and activated
T lymphocyte infiltration and by increased cytokine concentra-
tions such as tumor necrosis factor-alpha (TNF-a), inter-
leukins (IL)-6 and IL-8 [4,2,14]. Although nearly all smokers
show some evidence of lung and systemic cellular and/or
humoral inflammation, only a few will suffer an amplified
response and develop COPD. The aim of this study was to
identify whether the inflammatory process in stable COPD
patients is powerful enough to produce significant changes in
the selected inflammatory markers (TNF-a and hs CRP).
The role and levels of TNF-a and hs CRP in the peripheral
circulation of COPD patients and the relationship between
these biomarkers with prognostic factors in COPD will be
investigated and as we hypothesized that smoking exposure
will induce a different inflammatory signature, the impact of
smoking on inflammatory biomarkers in patients with
chronic obstructive pulmonary disease will be evaluated. With
the development of many new drugs that target inflammation
in COPD, there is a pressing need to identify reliable
biomarkers that may indicate whether an anti inflammatory
therapy is likely to have clinical benefit. A major problem is
the lack of any gold standard anti inflammatory therapy that
is effective in COPD, as a yardstick to compare potential
therapies.
Impact of smoking on inflammatory biomarkers 599Methods
This case–control observational prospective study was con-
ducted on fifty-eight clinically stable COPD patients (26 non-
smokers and 32 current smokers; at different stages ranged
from mild to very severe one, their mean age 53.1 ± 14.25
and 53.9 ± 5.95 years respectively), recruited from Chest
Department, Assiut University Hospitals. All patients met
the Global Initiative for Obstructive Lung Disease (GOLD)
[4] recommended spirometric criteria for COPD (ratio of
post-bronchodilator forced expiratory volume in one second
[FEV1] to forced vital capacity [FVC] less than 70%) [17].
The COPD patients were subdivided according to their treat-
ment into: thirteen patients use only short acting bronchodila-
tor as needed, the remaining forty five patients were using
long-term bronchodilators from those 45 patients, twenty
seven (13 COPD current smokers and 14 non-smokers)
patients were regularly using inhaled corticosteroid (800 mcg
of budesonide), sixteen patients of them had been on stable
oxygen flow therapy for the last six months. No patients were
medicated with theophylline or leukotriene modifiers.
Patients on oral steroid use or exacerbations in the last
three months before enrollment in the study, or diagnosed with
other respiratory disease like asthma, bronchiectasis, bronchi-
olitis or tuberculosis, or presence of other chronic diseases like
diabetes, renal failure, and cancer were excluded. In addition,
age, sex and BMI matched apparently healthy subjects with no
evidence of COPD or using regular medications for other
diseases from medical stuff and families who underwent health
examination at Assuit university hospitals were enrolled in the
study as control group; the controls were subdivided into
fifteen current smoker controls (at least 10 pack-years) and
fifteen never-smoker controls. All participants were subjected
to thorough history taking, full clinical examination, anthro-
pometric measurements with chest X-ray and spirometry.
Forced expiratory volume in the first second (FEV1) and
forced vital capacity (FVC) were obtained from the flow–
volume curve using a spirometer [Conventional spirometry
was a 10-Lclosed circuit Spirographs (Zan 300, Sensor Medics
MGA USB, Germany)] to study patients and control groups.
Static lung volumes were measured by closed-circuit helium
dilution method. The reference values used were those of the
American Thoracic Society standards) before and 20 min after
b-agonist (fenoterol 400 mcg) inhalation. The highest value of
at least three measurements was selected and expressed as a
percentage of reference values [18]. Venous blood samples were
collected from participants under standardized conditions.
Samples were centrifuged (3000g for 10 min) and serum
samples were divided and stored in aliquots at – 20 C until
analysis. Peripheral hemogram, liver function tests, kidney
function tests, High sensitivity C-reactive protein (hs-CRP)
measurement was done by Accu-Bind ELISA Microwells
(Monobind Inc., USA code 3125-300A lot EIA-31KIC2).
Assay of serum levels of TNF-a was performed using AviBion
Human TNF-a ELISA Kit (Orgenium, Finland, Rev 02.10).
Smoking history was calculated in pack-years as the product
of tobacco use (i current smoker n years) and the average num-
ber of cigarettes smoked per day/20 (years  cig. per day/20).
The study was approved by the Institutional Ethics Committee
of Faculty of Medicine, Assiut University and written
informed consent was obtained from each participant.Statistical analysis
Data were analyzed with Statistical package for social sciences
(SPSS) version 17 Chicago USA. Data were expressed as
mean ± SD or mean ± SE and frequencies according if they
are quantitative or qualitative respectively. Non-parametric
tests were used in the current study.
(1) Mann–Whitney Test (equivalent to independent Student’s
t test in parametric tests) was used for comparison of
quantitative variables among two independent groups.
(2) Wilcoxon Signed Ranks Test (equivalent to paired t test
in parametric tests) was used for comparison of quanti-
tative variables among two dependent groups.
(3) Chi-Square Test was used for comparison of distribu-
tion of qualitative variables among different groups.
(4) Comparisons between groups were achieved by Kruskal–
Wallis Test (equivalent to one way ANOVA test).
(5) Correlation between continuous variables was per-
formed using Spearman’s correlation coefficient.
P value < 0.05 is considered statistically significant.
Multiple regression analysis was used to determine indepen-
dent factors affecting dependent variables.
Results
Demographics, baseline lung function, and body mass index of
COPD and controls according to the smoking status of the
smokers are presented in Table 1 where it shows COPD
patients tended to have a nearly same age to controls regard-
less their smoking status with similar smoking history
(pack-years) in current smoker COPD patients and controls.
As expected, COPD patients had significant severe airflow
limitation and decreased SpO2 with highly significant decline
in FEV1 compared to controls.
Tables 2a, 2b, Tables 3a, 3b and Figs. 1 and 2 show highly
significant elevated levels of circulating TNF-a and hs-CRP in
COPD patients in comparison to the control group regardless
of their smoking status with significantly high levels in current
smoker patients and controls.
Table 4 shows the significant increased levels of the TNF-a
with the increased severity of COPD and increased grade of
dyspnea. Moreover, non significant differences for the mea-
sured TNF-a were found between the patients according to
the use of the inhaled corticosteroid therapy.
The regression results showed a highly significant positive
association among the measured TNF-a with smoking index,
increased degree of dyspnea and degree of COPD, while a
non significant positive association among the measured
hs-CRP with increased degree of dyspnea and degree of COPD
with a highly significant positive association among the
measured hs-CRP with smoking index is found in Table 5.
Table 6 shows highly significant positive associations
among the measured TNF-a and hs-CRP with smoking index
in COPD patients and current smoker controls.
Table 7 shows highly significant positive associations
among the measured TNF-a levels with FEV1 in COPD
patients and controls regardless of their smoking status. How-
ever, regarding the smoking status in COPD patients, there
was a highly significant positive association among current
Table 1 Demographic data, Pulmonary functions and blood gases among COPD patients compared to controls according to their
smoking status.
Variables Control non-smoker
(N= 15)
Control – smoker
(N= 15)
COPD non-smoker
(N= 26)
COPD smoker
(N= 32)
P-value
significance
FVC% pred 94.6 ± 8.47 91.8 ± 7.5 73.2 ± 3.6 71.5 ± 6.3 0.009*
RV% pred 92.3 ± 4.2 88.3 ± 4.2 129.33 ± 8.4 133.5 ± 12.4 0.004*
TLC% pred 91.7 ± 6.8 85.2 ± 3.4 127.8 ± 5.1 131.1 ± 10.6 0.003*
FEV1% pred 83.2 ± 3.1 81.5 ± 2.0 54.23 ± 23.4 51.6 ± 22.2 0.007*
FEV/FVC% 79.56 ± 9.1 76.4 ± 6.42 63.9 ± 5.46 59.2 ± 10.7 0.011*
Pa O2 mmHg 88.3 ± 6.3 82.6 ± 5.4 67.3 ± 4.9 61.5 ± 8.7 0.041
*
Pa CO2 mmHg 39.1 ± 3.6 40.5 ± 3.8 58.5 ± 8.4 61.3 ± 11.9 0.037
*
Age (years) 49.37 ± 14.37 52.56 ± 8 53.1 ± 14.25 53.9 ± 5.95 0.746
BMI (kg/m2 24.1 ± 5.0 24.2 ± 4.51 22.8 ± 4.9 21.4 ± 5.7 0.149
Kruskal–Wallis Test.
* Statistical significant difference.
Table 2a TNF-alpha (pg/ml).
Parameters Patients (n= 58) Controls (n= 30) P-value
Mean ± SE 35.88 ± 5.97 8.79 ± 0.57 0.000*
Range 3.7–265.5 3.7–14
Mann–Whitney Test.
* Statistical significant difference (P< 0.05).
Table 2b TNF-alpha (pg/ml).
Parameters Smoker Non-smoker P-value
Mean ± SE Mean ± SE
Patients 53.74 ± 9.52 12.73 ± 1.20 0.000*
Controls 10.70 ± 0.60 6.88 ± 0.69 0.001*
Mann–Whitney Test.
* Statistical significant difference (P< 0.05).
Table 3a Hs-CRP (lg/ml).
Parameters Patients (n= 58) Controls (n= 30) P-value
Mean ± SE 3.74 ± 0.20 1.30 ± 0.14 0.000*
Range 1.2–8.0 0.2–2.5
Mann–Whitney Test.
* Statistical significant difference (P< 0.05).
Table 3b Hs-CRP (lg/ml).
Parameters Smokers Non-smokers P-value
Mean ± SE Mean ± SE
Patients 3.87 ± 0.29 3.58 ± 0.27 0.764
Controls 1.96 ± 0.14 0.64 ± 0.06 0.000*
Mann–Whitney Test.
* Statistical significant difference (P< 0.05).
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between FEV1 with the measured hs-CRP. In controls regard-
less of their smoking status highly significant positive associa-
tions among the measured hs-CRP with FEV1 were detected.Discussion
Chronic obstructive pulmonary disease (COPD) is a slowly
progressive disease induced primarily by smoking tobacco.
Other etiological factors of COPD, like air pollution, poor
nutrition, professional risk at work and genetic factors may
have probably participated. The pathophysiology of COPD
is not completely understood. [45]. According to Global
Initiative on Obstructive Lung Disease (GOLD) definition,
‘‘the airflow limitation in COPD is not fully reversible and is
usually progressive and associated with an abnormal inflam-
matory response of the lungs to noxious particles and gases”
[44]. In the interest of improving the diagnosis of COPD,
several types of biomarkers have been measured that are
related to disease pathophysiology and the inflammatory and
destructive process in the lung. The aim of this study was to
identify whether the inflammatory process in stable COPD
patients is powerful enough to produce significant changes in
the selected inflammatory markers (TNF-a and hs CRP) and
to evaluate the relationship between systemic inflammation
and smoking status in COPD patients.
CRP is an acute phase protein synthesized predominantly
by the hepatocytes in response to tissue damage or inflamma-
tion. It has been accepted that levels of CRP relate to the pres-
ence of airflow obstruction. Elevated CRP has been known to
be used as a surrogate marker of systemic inflammation in
diverse conditions [44]. Interestingly, our study in fact, showed
that the serum level of hs CRP was highly significantly elevated
in COPD patients compared with controls regardless of their
smoking status. This result confirms that the higher levels of
circulating hs CRP may be thus regarded as a valid biomarker
of low-grade systemic inflammation in the COPD. Our results
were in agreement with [43] who reported that COPD patients
had higher levels of hs-CRP due to the fact of the earlier
response of hs-CRP, as it is secreted as acute phase reactants
by the liver in response to IL-6. Moreover, [8,11,1] stated that
systemic inflammation in COPD patients is associated with
increased neutrophil, macrophage, and T-lymphocyte numbers
and high concentrations of inflammatory mediators in
peripheral blood (C-reactive protein (CRP) and TNF-a). Their
study showed a significantly higher levels of circulating hs
CRP in COPD patients than in smoking and non smoking
controls. However, the level of hs CRP in the smoking COPD
Figure 1 Levels of TNF-alpha in COPD patients and controls (pg/ml) according to their smoking status.
Figure 2 Levels of hs-CRP in COPD patients and controls
(lg/ml) according to their smoking status.
Table 4 Mean levels of circulating TNF-alpha according to
an increased degree of COPD, the severity of dyspnea and the
steroid inhalation therapy in COPD patients.
Parameters Mean ± SE P-value
Degree of COPD 0.000*
Mild 10.16 ± 0.92
Moderate 21.86 ± 0.92
Severe 46.63 ± 4.39
Very severe 149.90 ± 33.04
Dyspnea 0.000*
Grade II 17.06 ± 1.49
Grade III 38.76 ± 5.09
Grade IV 137.26 ± 30.66
Steroid inhalation therapy 0.077
Yes 29.61 ± 12.33
No 46.16 ± 9.29
Kruskal–Wallis Test.
* Statistical significant difference (P< 0.05).
Table 5 Regression models with robust standard errors for
TNF-a and CRP in COPD Patients.
Parameters TNF-alpha(pg/ml) Hs CRP(lg/ml)
r-value P-value r-value P-value
Smoking index 0.850 0.000* 0.614 0.000*
Degree of COPD 0.936 0.000* 0.198 0.122
Grades of dyspnea 0.708 0.000* 0.179 0.163
Spearman’s correlation.
* Statistical significant difference (P< 0.05).
Table 6 Correlation between the measured TNF-alpha and
hs-CRP versus smoking index in COPD patients and control
groups.
Variables Smoking index
r-value P-value
Patient smokers TNF-alpha 0.788 0.000*
Hs CRP 0.614 0.000*
Control smokers TNF-alpha 0.889 0.000*
Hs CRP 0.858 0.000*
Spearman’s correlation.
* Statistical significant difference (P< 0.05).
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smoking patients. We suggest that, although cigarette smoking
has a role in promoting inflammatory process in COPD
patients, it is not the leading cause of increased inflammatorymarkers. it should be noticed that only some cases develop
inflammatory reaction following cigarette smoking, and this
can be due to genetic differences. In contrast to the above
findings, [44], showed the level of hs CRP in the smoking
COPD population remained significantly higher than in the
non-smoking patients.
TNF-a, a powerful pro-inflammatory cytokine primarily
produced by activated macrophages, is thought to a critical
role in the pathogenesis of COPD by promoting and maintain-
ing the expression and release of various proinflammatory
mediators which lead to tissue damage and remodeling [13].
Very little is known about the mechanism of increased
TNF-a concentration in the plasma of COPD patients and
its relationship with disease severity and active smoking has
not been established [9,15]. However, Marevic et al., 2008
reported that tobacco smoking induces the release of TNF-a
and has an important role in the pathophysiology of COPD.
Table 7 Correlation between the measured TNF-alpha and
hs-CRP versus FEV1 in COPD patients and controls regarding
to their smoking status.
Variables FEV1
r-value P-value
COPD smokers TNF-alpha 0.843 0.000*
hsCRP 0.501 0.002*
COPD non-smokers TNF-alpha 0.464 0.015*
hsCRP 0.067 0.741
Control smokers TNF-alpha 0.881 0.000*
hsCRP 0.848 0.000*
Control non-smokers TNF-alpha 0.879 0.000*
hsCRP 0.857 0.000*
Spearman’s correlation.
* Statistical significant difference (P< 0.05).
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endothelin-1 (ET-1) in human endothelial cells, and participates
in bronchoconstriction through secondary release of ET-1.
Our study showed that the level of serum inflammatory
marker; TNF-a was highly significantly elevated in COPD
patients regardless of their smoking status indicating a persis-
tent systemic inflammation in subjects with COPD with signif-
icantly high levels of TNF-a in current COPD smokers. These
results suggest that smoking may be associated with higher
TNF-a mediated systemic inflammation in COPD patients.
These findings were in agreement with [13] who reported the
increased levels of serum TNF-a, IL-6 and tissue inhibitors
of metalloproteinase-1 in asthma and COPD patients with
highest levels in current smoker COPD patients and controls.
Moreover, our results were in consistent with those of [11,1],
Marevic et al., 2008, [45] who reported a significant increase
in serum inflammatory markers TNF-a, hs CRP and
interlukin-6 in different stages of COPD patients and this
increment was significantly higher than those of the controls.
We may thus speculate the association of smoking with higher
systemic TNF-a levels observed in this study may partially
explain some benefits associated with smoking cessation. In
contrast to our findings, Vernooy et al. [17] reported an
increase in the concentration of soluble TNF-a receptors,
while the concentration of TNF-a was within the reference
range for healthy individuals. Possible explanation for
unchanged concentration of TNF-a is its local and short term
effects, its degradation and its half life of approximately
6–7 min, as well as its binding to receptors and renal clearance.
FEV1 is easily measured and is a spirometric predictor of
mortality in patients with COPD. Factors that affect the
decline of FEV1 are, therefore, of prognostic importance in
COPD [45]. Our study revealed the increased TNF-a levels
in COPD patients with increased airway obstruction severity,
increased and degree of dyspnea with a significant negative
correlation between TNF-a with FEV1. These results clearly
confirm the fact that the intensity of the inflammatory process
in COPD could be related to the severity of the underlying
disease. Our findings were in agreement with [40] who stated
the higher serum TNF-a levels in COPD patients were associ-
ated with patients with severe COPD in comparison withmild-moderate COPD patients. Furthermore, Kostikas et al.
[12] and Samy et al. [45] reported TNF-a levels increased
according to the stage of the COPD. Interestingly, non
significant higher hs-CRP concentrations associated with
increased severity of airway obstruction and an increased
degree of dyspnea were observed in our study. These findings
were in agreement with [37,15] who reported that higher
hs-CRP concentration has been associated with airway
obstruction severity, increased resting energy expenditure,
and impaired exercise capacity and quality of life in COPD
patients [44] concluded that the circulating levels of the
inflammatory marker hs-CRP are significantly elevated in
patients with COPD, supporting the view that COPD is in part
an inflammatory disorder. Hs-CRP levels in stable COPD
patients are best correlated with FEV1 and 6-minute walk
distance (6MWD). Clearly, in the our study hs CRP levels were
inversely correlated with FEV1 in stable COPD patients. The
strongest negative association between FEV1 and CRP and
higher CRP levels over time were associated with a faster
FEV1 decline. These results were consistent with those of
Man et al., 2006 and [44] who stated CRP levels associated
with accelerated decline in FEV1 and mortality in patients
with mild to moderate COPD, indicating that CRP measure-
ments might enable identification of patients at high risk of
disease progression and mortality.
Tobacco smoking is the main risk factor of chronic obstruc-
tive pulmonary disease (COPD) but not all smokers develop
the disease. An abnormal pulmonary and systemic inflamma-
tory response to smoking is thought to play a major patho-
genic role in COPD, but this has never been tested directly.
Long-term smoking causes airway inflammation characterized
by neutrophil, macrophage, and activated T lymphocyte infil-
tration and by increased cytokine concentrations such as
tumor necrosis factor-alpha (TNF-a), interleukins (IL)-6 and
IL-8 [4,2]. Although nearly all smokers show some evidence
of lung and systemic cellular and/or humeral inflammation,
only a few will suffer an amplified response and develop
COPD.
Interestingly, highly significant higher concentrations of
TNF-a and hs-CRP in COPD patients associated with an
increased severity of smoking status were observed in our
study. The correlations of TNF-a and hs CRP concentration
with smoking habit (pack/years) supports the assumption that
tobacco smoke has an influence on systemic inflammation.
Hs-CRP and TNF-a indicate that COPD is a systemic
inflammatory disease, and they could serve as predictors for
exacerbations. However, it is unclear whether established
inflammation in smokers returns to normal after smoking ces-
sation. Smoking cessation is the only management measure
associated with reduced FEV1 decline in COPD patients;
however, to date, no reduction in airway inflammation has
been demonstrated when ex-smokers are compared to current
smokers by Gamble et al. [2] who did not find any differences
in cell counts or inflammatory markers (CD8+, CD4+,
CD 68+, or TNF-a) in bronchial biopsies of COPD current
smokers and COPD ex-smokers. Nevertheless, [33] reported
that neutrophil and lymphocyte numbers, and IL-8 concentra-
tion in the sputum of COPD patients were increased one year
after smoking cessation.
Unfortunately, we could not reveal the influence of inhaled
corticosteroids on systemic inflammation in COPD patients
owing to small sized sample used, more researches with larger
Impact of smoking on inflammatory biomarkers 603sample size and longer observation time needed to detect
potential differences and to confirm these results.
Conclusions
The circulating levels of the inflammatory markers hs-CRP
and TNF-alpha are significantly elevated in patients with
COPD, supporting the view that COPD is in part an inflam-
matory disorder. These circulating biomarkers in stable COPD
patients are best correlated with FEV1 suggesting that these
circulating biomarkers are good candidates as predictors for
rapid decline of FEV1 in COPD, although a larger size study
with a longer term observation is needed to confirm these
findings. It is likely that in the future biomarkers will become
increasingly required to aid in determining those patients who
will benefit from a given drug therapy to improve risk and/or
cost benefit, especially since it is becoming more widely consid-
ered in COPD. Smoking is associated with higher levels of
TNF-alpha and hs-CRP mediated systemic inflammation in
patients with or without COPD, therefore active smoking
maybe associated with even a higher degree of the systemic
inflammation. Longitudinal studies evaluating the effects of
smoking cessation on bronchial and systemic inflammation
are needed to allow better understanding of these relationships
and their consequences.
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